Astellas Deal History & Licensing Activity
Astellas is a large pharma headquartered in Japan. Over the past three years, Astellas has been involved in 5 licensing and acquisition transactions, with a primary focus on ADC (3 deals). The company currently has 50 active clinical trials, primarily in Solid Tumors.
Deals (12mo)
4
Active Trials
50
Top Modality
ADC
Focus Area
Solid Tumors
Astellas Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Astellas in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| isaralgagene civaparvovec (ST-920) | Astellas Pharma Inc. | Gene Therapy | Phase 1 | acquisition | Jun 23, 2026 |
| Undisclosed | Astellas Pharma | Other | Discovery | collaboration | Mar 26, 2026 |
| VIR-5500 | Astellas Pharma | Bispecific Antibodies | Phase 1 | collaboration | Feb 24, 2026 |
| AJICAP ADC technology | Astellas Pharma | ADC | Unknown | license | Oct 31, 2025 |
Astellas Pipeline Focus
Therapeutic areas and modalities where Astellas is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Astellas Strategic Signals
Key indicators of Astellas's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
Astellas Clinical Pipeline
Astellas has 50 active clinical trials across 7 development phases.
2
Phase 4
8
Unknown
1
Not Applicable
20
Phase 1
2
Phase 1/2
10
Phase 2
7
Phase 3
See How Your Asset Matches Astellas's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Solid Tumors assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
ADC Benchmarks
Upfront, milestone, and royalty benchmarks for adc deals
Gene Therapy Benchmarks
Upfront, milestone, and royalty benchmarks for gene therapy deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Astellas Licensing & Deal Activity
Astellas is a large pharma company based in Japan that has been actively engaged in licensing transactions across the biopharma landscape. With 5 deals over the past three years, Astellas ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Astellas include Solid Tumors (25 deals and trials), Hematological Malignancies (5 deals and trials), Oncology (4 deals and trials), and Rare Disease (2 deals and trials). In terms of modality, Astellas has shown particular interest in adc, gene therapy, other.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Astellas and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Astellas's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.